Supportive care in multiple myeloma

Simit Mahesh Doshi, Tom T. Noff, G. David Roodman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy, affecting more than 60,000 patients in the United States with 30,000 patients diagnosed in 2016 (Leukemia 28(5):981-992, 2014; ACS 2016, http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-key-statistics. MM is the most common malignancy to affect bone with 70% of patients presenting with bone disease at diagnosis, and up to 85% of MM patients will have bone complications over the course of their disease (Leukemia 28(2):398-403, 2014). In addition, approximately 20% of patients will have renal dysfunction and 5% will have clinically detectable neuropathy at diagnosis (Arch Intern Med 158(17):1889-1893, 1998; Best Pract Res Clin Haematol 18(4):673-688, 2005). Further, renal dysfunction and neuropathy can increase during the course of their disease secondary to toxicities associated with therapy for the bone disease, treatment of their MM, or disease progression. In addition, MM patients are at increased risk for thrombosis because of their underlying malignancy, as well as immunomodulatory therapies that enhance the risk of thrombosis (Leukemia 22(2):414-423, 2008). Erythropoiesis-stimulating agents can further exacerbate the incidence of thrombosis in MM patients. In this chapter, the underlying pathophysiology of bone, renal and neuropathic abnormalities associated with MM, current approaches to their treatment, and new therapies to prevent or treat the complications of MM therapies are discussed.

Original languageEnglish (US)
Title of host publicationNeoplastic Diseases of the Blood
PublisherSpringer International Publishing
Pages595-607
Number of pages13
ISBN (Electronic)9783319642635
ISBN (Print)9783319642628
DOIs
StatePublished - Jan 1 2018

Fingerprint

Multiple Myeloma
Leukemia
Thrombosis
Bone Diseases
Kidney
Bone and Bones
Neoplasms
Hematinics
Therapeutics
Immunomodulation
Hematologic Neoplasms
Disease Progression
Incidence

Keywords

  • Bone disease
  • Kidney disease
  • Myeloma
  • Neuropathy
  • Thromboprophylaxis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Doshi, S. M., Noff, T. T., & Roodman, G. D. (2018). Supportive care in multiple myeloma. In Neoplastic Diseases of the Blood (pp. 595-607). Springer International Publishing. https://doi.org/10.1007/978-3-319-64263-5_31

Supportive care in multiple myeloma. / Doshi, Simit Mahesh; Noff, Tom T.; Roodman, G. David.

Neoplastic Diseases of the Blood. Springer International Publishing, 2018. p. 595-607.

Research output: Chapter in Book/Report/Conference proceedingChapter

Doshi, SM, Noff, TT & Roodman, GD 2018, Supportive care in multiple myeloma. in Neoplastic Diseases of the Blood. Springer International Publishing, pp. 595-607. https://doi.org/10.1007/978-3-319-64263-5_31
Doshi SM, Noff TT, Roodman GD. Supportive care in multiple myeloma. In Neoplastic Diseases of the Blood. Springer International Publishing. 2018. p. 595-607 https://doi.org/10.1007/978-3-319-64263-5_31
Doshi, Simit Mahesh ; Noff, Tom T. ; Roodman, G. David. / Supportive care in multiple myeloma. Neoplastic Diseases of the Blood. Springer International Publishing, 2018. pp. 595-607
@inbook{0f2b3fa5fdd343bfbdb6e85882b2925e,
title = "Supportive care in multiple myeloma",
abstract = "Multiple myeloma (MM) is the second most common hematologic malignancy, affecting more than 60,000 patients in the United States with 30,000 patients diagnosed in 2016 (Leukemia 28(5):981-992, 2014; ACS 2016, http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-key-statistics. MM is the most common malignancy to affect bone with 70{\%} of patients presenting with bone disease at diagnosis, and up to 85{\%} of MM patients will have bone complications over the course of their disease (Leukemia 28(2):398-403, 2014). In addition, approximately 20{\%} of patients will have renal dysfunction and 5{\%} will have clinically detectable neuropathy at diagnosis (Arch Intern Med 158(17):1889-1893, 1998; Best Pract Res Clin Haematol 18(4):673-688, 2005). Further, renal dysfunction and neuropathy can increase during the course of their disease secondary to toxicities associated with therapy for the bone disease, treatment of their MM, or disease progression. In addition, MM patients are at increased risk for thrombosis because of their underlying malignancy, as well as immunomodulatory therapies that enhance the risk of thrombosis (Leukemia 22(2):414-423, 2008). Erythropoiesis-stimulating agents can further exacerbate the incidence of thrombosis in MM patients. In this chapter, the underlying pathophysiology of bone, renal and neuropathic abnormalities associated with MM, current approaches to their treatment, and new therapies to prevent or treat the complications of MM therapies are discussed.",
keywords = "Bone disease, Kidney disease, Myeloma, Neuropathy, Thromboprophylaxis",
author = "Doshi, {Simit Mahesh} and Noff, {Tom T.} and Roodman, {G. David}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-64263-5_31",
language = "English (US)",
isbn = "9783319642628",
pages = "595--607",
booktitle = "Neoplastic Diseases of the Blood",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Supportive care in multiple myeloma

AU - Doshi, Simit Mahesh

AU - Noff, Tom T.

AU - Roodman, G. David

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Multiple myeloma (MM) is the second most common hematologic malignancy, affecting more than 60,000 patients in the United States with 30,000 patients diagnosed in 2016 (Leukemia 28(5):981-992, 2014; ACS 2016, http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-key-statistics. MM is the most common malignancy to affect bone with 70% of patients presenting with bone disease at diagnosis, and up to 85% of MM patients will have bone complications over the course of their disease (Leukemia 28(2):398-403, 2014). In addition, approximately 20% of patients will have renal dysfunction and 5% will have clinically detectable neuropathy at diagnosis (Arch Intern Med 158(17):1889-1893, 1998; Best Pract Res Clin Haematol 18(4):673-688, 2005). Further, renal dysfunction and neuropathy can increase during the course of their disease secondary to toxicities associated with therapy for the bone disease, treatment of their MM, or disease progression. In addition, MM patients are at increased risk for thrombosis because of their underlying malignancy, as well as immunomodulatory therapies that enhance the risk of thrombosis (Leukemia 22(2):414-423, 2008). Erythropoiesis-stimulating agents can further exacerbate the incidence of thrombosis in MM patients. In this chapter, the underlying pathophysiology of bone, renal and neuropathic abnormalities associated with MM, current approaches to their treatment, and new therapies to prevent or treat the complications of MM therapies are discussed.

AB - Multiple myeloma (MM) is the second most common hematologic malignancy, affecting more than 60,000 patients in the United States with 30,000 patients diagnosed in 2016 (Leukemia 28(5):981-992, 2014; ACS 2016, http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-key-statistics. MM is the most common malignancy to affect bone with 70% of patients presenting with bone disease at diagnosis, and up to 85% of MM patients will have bone complications over the course of their disease (Leukemia 28(2):398-403, 2014). In addition, approximately 20% of patients will have renal dysfunction and 5% will have clinically detectable neuropathy at diagnosis (Arch Intern Med 158(17):1889-1893, 1998; Best Pract Res Clin Haematol 18(4):673-688, 2005). Further, renal dysfunction and neuropathy can increase during the course of their disease secondary to toxicities associated with therapy for the bone disease, treatment of their MM, or disease progression. In addition, MM patients are at increased risk for thrombosis because of their underlying malignancy, as well as immunomodulatory therapies that enhance the risk of thrombosis (Leukemia 22(2):414-423, 2008). Erythropoiesis-stimulating agents can further exacerbate the incidence of thrombosis in MM patients. In this chapter, the underlying pathophysiology of bone, renal and neuropathic abnormalities associated with MM, current approaches to their treatment, and new therapies to prevent or treat the complications of MM therapies are discussed.

KW - Bone disease

KW - Kidney disease

KW - Myeloma

KW - Neuropathy

KW - Thromboprophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85047033664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047033664&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-64263-5_31

DO - 10.1007/978-3-319-64263-5_31

M3 - Chapter

SN - 9783319642628

SP - 595

EP - 607

BT - Neoplastic Diseases of the Blood

PB - Springer International Publishing

ER -